Biotech Week articles from July 2004

Biotech Week archives from July 2004

Report: Islet cell transplant program for type 1 diabetes successful.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- The Edmonton Protocol for transplanting islets, through an injection that frees people with diabetes from daily insulin injections, has been shown to be effective and safe in its first international...

Enrollment completed in trial of paclitaxel-loaded vascular wrap.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Angiotech Pharmaceuticals, Inc., (ANPI; ANP) announced that it has completed the enrollment of its vascular wrap study, approximately 6 months earlier than anticipated. Patients suffering from poor...

Data released on Canvaxin in treatment of patients with Stage IV melanoma.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- CancerVax Corporation (CNVX) announced that data from retrospective analyses show that treatment with Canvaxin, the company's investigational specific active immunotherapy, significantly improved median...

Discovery of tumor vascular targets may mean safer cancer treatment.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- A discovery by researchers at the Sidney Kimmel Cancer Center (SKCC) holds the promise of taking treatment of several types of cancer to a much higher level of safety and effectiveness. The...

Subterfuge enables gene therapy to cross the blood-brain barrier.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Subterfuge enables gene therapy to cross the blood-brain barrier. "Many chronic neurological diseases do not respond to small molecule therapeutics, and have no effective long-term therapy. Gene...

Results reported from phase I trial of Perifosine combined with radiotherapy.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- AEterna Zentaris, Inc., (AEZ; AEZS) announced encouraging final results from recently completed phase I trial evaluating perifosine, the company's novel, first-in-class, oral AKT inhibitor, in...

Miniaturized RNAi gene knockdown experiments performed in primary cells.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Miniaturized RNAi gene knockdown experiments can now be performed in primary cells. According to recent research from Japan, "The transfection efficiency of primary cells is the bottleneck for their...

Data regarding intraoperative radiotherapy for early breast cancer is unclear.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Data regarding intraoperative radiotherapy for early breast cancer is unclear. According to a study from Australia, "a systematic review was undertaken to assess the safety and efficacy of...

Placement of bone tunnels for ACL reconstruction reviewed.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- The optimal placement of bone tunnels for anterior cruciate ligament (ACL) reconstruction has been reviewed. The reconstruction of a ruptured ACL is "a frequently performed operation," however,...

Psychiatric health of dermatology patients is an important aspect of care.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Patients with dermatologic ailments often have disease-related psychological problems, which should be addressed as part of the patients' care. Researchers in Denmark "[compared] psychological...

Diabetes management system launched.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Abbott Laboratories (ABT) introduced the new and improved Precision Xtra Advanced Diabetes Management System at the American Diabetes Association's 64th Annual Scientific Sessions and Exposition in...

FDA accuses maker of antiretroviral of misleading promotions.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- The U.S. Food and Drug Administration (FDA) has accused Abbott Laboratories, Inc., of providing the public with misleading information about a drug used to treat HIV infection, saying the promotional...

FDA issues warning letter regarding Norvir.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Abbott Laboratories has received a warning letter from the U.S. Food and Drug Administration's Division of Drug Marketing Advertising and Communications (DDMAC) outlining concerns related to the website...

Data: Panitumumab has single-agent antitumor activity in colorectal cancer.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Amgen, Inc., (AMGN), and Abgenix (ABGX), an antibody-development company, announced interim data from an ongoing phase II study demonstrating that panitumumab (formerly ABX-EGF), a fully human...

CareSouth acquires California home health company.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- CareSouth, Augusta, Georgia-headquartered home care and business services provider, has announced the acquisition of Able Home Health, Inc., of Santa Clarita, California. Complete ownership of Able...

Elective single embryo transfer percentage reflects quality of institution.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Assisted reproduction centers should strive for fewer embryo transfers, and researchers say that the elective single embryo transfer (eSET) is the most important indicator of the quality of such...

Biomarker study focuses on indicators of Herceptin responsiveness.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Aclara BioSciences (Nasdaq: ACLA) and the Tokyo Metropolitan Institute of Medical Science (Rinshoken) have entered into an agreement to collaborate on a study to evaluate breast cancer patient samples...

Biotechnology company announces new appointment to scientific advisory board.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Aclara BioSciences (NASDAQ:ACLA) announced that Jose Baselga, MD, has been appointed to its scientific advisory board. Baselga is professor of medicine at the Universidad Autonoma de Barcelona and...

Phase I study of porous nanoparticle formulation of paclitaxel complete.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Acusphere, Inc., (ACUS) announced that it has completed a phase I human safety study of its AI-850 product. AI-850 is a Cremophor-free formulation of paclitaxel, the active ingredient in Taxol, a...

Radiotherapy during pregnancy requires careful choice of linear accelerator.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- It is preferable to withhold radiotherapy on pregnant women with cancer, but should it be unavoidable, researchers have revealed data on fetal dose estimates and risk assessment. "Cancer in...

Exherin clinical data released.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Adherex Technologies, Inc., (AHX) released initial results from the phase I study of its anticancer drug, Exherin, at a major international cancer conference. Exherin is a small peptide molecule...

Neuromodulation company comments on acquisition of Advanced Bionics.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Advanced Neuromodulation Systems, Inc., (ANS, ANSI) commented on Boston Scientific Corporation's recent announcement that it will acquire Advanced Bionics Corporation for $740 million in cash plus...

Results of AVR118 phase I/II clinical program presented at ASCO.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Advanced Viral Research Corp. (ADVR) announced that the company presented interim results of its phase I/II clinical program with its flagship product, AVR118, at The American Society of Clinical...

Positive data reported for CoFactor, VEGF antibody, 5-FU combination.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Adventrx Pharmaceuticals, Inc., (ANX) announced positive results using CoFactor in combination with 5-fluorouracil (5-FU) and an antibody-based inhibitor of vascular endothelial growth factor...

Respimat SMI provides improved ipratropium bromide/fenoterol delivery.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- A novel inhaler provides improved drug delivery to COPD patients. Researchers in England "performed a multicenter, randomized, double-blind (within-device), placebo- and active-controlled,...

Saforis reduces severity of oral mucositis in chemotherapy study patients.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Aesgen, Inc., announced results from its pivotal phase III trial that show Saforis (L-glutamine) for oral suspension significantly reduced the severity and duration of clinically significant oral...

Device maker completes $673,000 private placement.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Aethlon Medical, Inc., (AEMD) announced that it has completed a $673,000 private placement of common stock with accredited investors, including Fusion Capital Fund II LLC, a Chicago based institutional...

AHRQ makes access to hospital data easier.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- The Agency for Healthcare Research and Quality has redesigned its interactive HCUPnet software tool (available on the web at www.ahrq.gov/hcupnet/) to make it easier to obtain hospital care trend data...

Results from phase I/II cancer trials with rhLF presented at ASCO.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- The Department of Hematology/Oncology at the Veterans Affairs Medical Center (VAMC), Houston, Texas, and Agennix Inc., disclosed results from two phase I/II cancer trials with oral recombinant human...

Tool launched for standardized measurement of RNA quality.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Agilent Technologies, Inc., (A) introduced the first tool to measure RNA quality and grade it on a quantitative scale of 1 to 10. This measurement, known as the RNA integrity number (RIN), makes it...

Drugs given away by AIDS patients in U.S. prolong lives worldwide.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Jose Clemente, who restores artworks in Mexico's capital, has never met Daphne Rivera, a Brooklyn health educator. But medicines donated by Rivera are keeping Clemente alive. From Mexico to...

Diminished lung compliance found in nutritionally obese young rats.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Lung compliance is diminished and surfactant lipids and proteins are elevated in nutritionally obese young rats. According to recent research published in the journal Lung, "Dietary-induced obesity...

Pharmaceutical company receives commitments for $11M financing.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Alliance Pharmaceutical Corp. (ALLP) announced that it has entered into definitive purchase agreements with respect to the private placement of 31,427,137 shares of Alliance Pharmaceutical Corp.'s...

Data from phase III trial of radiation sensitizer presented at ASCO.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Allos Therapeutics, Inc., (ALTH) announced that results from its phase III clinical trial of the investigational radiation sensitizer RSR13 (efaproxiral) in patients with brain metastases were presented...

Phase III trial data suggest some lung cancer patients may benefit from RSR13.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Allos Therapeutics, Inc., (ALTH) announced that a retrospective analysis of the results from its phase III trial of the investigational radiation sensitizer RSR13 (efaproxiral) in patients with brain...

Biotech company announces entry into European surgical devices market.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Alltracel Pharmaceuticals Plc, (AP.L) announced its entry into the post and inter operative surgical market with the third quarter launch by one of the world's leading medical device companies of an...

Biopharmaceutical firm exercises underwriters' over-allotment option.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Alnylam Pharmaceuticals, Inc., (ALNY) announced that the underwriters of its recent initial public offering of 5,000,000 shares of common stock have exercised in full their over-allotment option to...

Insulin patch maker expands its capabilities with new directors.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Altea Therapeutics announced the appointment of three new directors from the pharmaceutical industry as it broadens the leadership of its product development programs. The company's lead clinical...

Medical advisory board formed by stent company.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Alveolus, Inc., a developer of non-vascular interventional stent technology announced the formation of its newly organized Thoracic Advisory Board. Alveolus, whose products are developed for...

Prevalence, exposure to mouse allergen may contribute to asthma.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Mouse allergen has a widespread presence in U.S. homes and may contribute to the development of asthma, according to a study featured in the June 2004 Journal of Allergy and Clinical Immunology (JACI)....

Doctors' group rejects proposal to soften "freebie" policy.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- The American Medical Association has rejected a proposal that would have softened the group's stance against drug industry "freebies," including paying for doctors' trips to industry-sponsored...

Results reported in trial of Abraxane for advanced breast cancer patients.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Abraxis Oncology, a division of American Pharmaceutical Partners, Inc., (APP, APPX) said that results from a 106 patient phase II study of Abraxane in patients with advanced breast cancer whose disease...

Novel gene therapy approach suppresses autoimmune encephalomyelitis.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Scientists have developed a novel retroviral gene therapy approach to inhibit specific antibody production and suppress experimental autoimmune encephalomyelitis induced by MOG and MBP. ...

MabCampath continues to improve survival for patients with CLL.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Data from two related studies confirm the ability of MabCampath (alemtuzumab) to clear leukemic cells from the bone marrow of chronic lymphocytic leukemia (CLL) patients, a result known as eradication...

NSABP protocol C-06: Oral chemotherapy equally effective and tolerated.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Five-year results of NSABP (National Surgical Adjuvant Breast and Bowel Project) Protocol C-06 that compared oral chemotherapy (UFT/leucovorin) with intravenous chemotherapy (5-FU/leucovorin)...

Advancements in imaging enhance diagnosis, treatment of neurological diseases.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Neuroscience and radiology experts shared new research and technological developments in medical imaging that facilitate diagnosis and breakthrough treatments of fetal brain abnormalities, epilepsy and...

Aranesp corrects chemotherapy-induced anemia when dosed once every 3 weeks.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Amgen Inc. (AMGN) announced results of a new study demonstrating that Aranesp (darbepoetin alfa) dosed once every 3 weeks achieved and maintained the target hemoglobin levels recommended by clinical...

Studies: Aranesp dosed semiweekly is comparable to epoetin alfa once a week.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Amgen, Inc., (AMGN) presented final results from an analysis of three identical head-to-head trials showing that Aranesp (darbepoetin alfa) dosed once every 2 weeks provided similar results as epoetin...

Exenatide studies show significant improvements in glucose control, weight loss.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Amylin Pharmaceuticals, Inc., (AMLN) and Eli Lilly and Co. (LLY) presented detailed 30-week data from two of the three pivotal phase III studies of exenatide during the American Diabetes Association's...

Oncophage cancer vaccine clinical findings announced.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Antigenics Inc. (AGEN) announced findings from two clinical trials of the company's investigational cancer vaccine Oncophage (HSPPC-96). Demographic data from the company's phase III trial of...

Australian company addresses two common and debilitating eye diseases.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- With an aging population and increasing prevalence of diabetes, Australia can expect a surge in the incidence of blindness. Two major causes of blindness are diabetic retinopathy and wet age-related...

Positive results reported from phase I trial of ATL-1102 for MS.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Antisense Therapeutics Limited and Isis Pharmaceuticals, Inc., (ISIS) announced the results of a dose-escalating phase I study of ATL-1102. Based on the study's results 6 mg/kg/week of ATL-1102...

Severe infections plague acute alcoholic hepatitis patients given infliximab.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Severe infections plague acute alcoholic hepatitis patients given infliximab. According to published research from France, "tumor necrosis factor-alpha (TNF-alpha) may contribute to the progression...

Regulatory submission of pancreatic cancer therapy begins in Switzerland.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Aphton (APHT) announced that it has begun submission of regulatory documentation to the Swiss Agency for Therapeutic Products (Swissmedic), the regulatory authority in Switzerland, for the registration...

Phase IIa trial starts for rheumatoid arthritis drug.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Arakis, Ltd., has initiated a phase IIa clinical trial in 96 rheumatoid arthritis (RA) patients to study the pharmacokinetics, safety and tolerability of a range of doses of AD 452, a novel disease...

ADP-specific sensors enable universal assay of protein kinase activity.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- ADP-specific sensors enable a universal assay of protein kinase activity. "Two molecular sensors that specifically recognize ADP in a background of over 100-fold molar excess of ATP are described....

Improved throughput protein precipitation method presented.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Argonaut Technologies (AGNT) presented a poster on a new protein precipitation filterplate at the 2004 American Society of Mass Spectrometry (ASMS) conference in Nashville, Tennessee. In the...

Device company announces preliminary fiscal 2005 guidance.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- ArthroCare Corp. (ARTC), a medical device company that develops minimally invasive surgical products, announced preliminary financial guidance for its fiscal year 2005. The company's guidance is as...

Device maker announces sale of common stock to Boston Scientific.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Aspect Medical Systems, Inc., (ASPM) announced that it has completed the sale of 500,000 shares of its common stock to Boston Scientific Corporation. The purchase price per share was $16.21, and the...

Study investigates resistance to tamoxifen and possible way to reverse it.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- A new study has found a possible mechanism for tamoxifen resistance in breast cancer and provides evidence that another cancer drug - gefitinib (AstraZeneca brand name: Iressa) - may be able to restore...

Results reported for IRESSA in non-small cell lung cancer patients.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Final data from more than 21,000 non-small cell lung cancer patients who received the oral cancer drug IRESSA (gefitinib) through AstraZeneca's preapproval expanded access program (EAP) in the United...

Anthrax antibody profiled in medical journal.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Avanir Pharmaceuticals' (AVN) anti-anthrax monoclonal antibodies protected rats from lethal anthrax toxins, according to a study published in the peer-reviewed Journal of Immune Based Therapies and...

Diagnostic scale used in phase III trial to identify pseudobulbar affect.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Avanir Pharmaceuticals (AVN) announced that information on a diagnostic scale used to identify pseudobulbar affect (PBA) in patients with multiple sclerosis (MS) was presented at the 2004 Annual...

Morwell added as partner to list of diagnostics distributors.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Avitar, Inc., (AVR) announced that it is adding Morwell Diagnostics GmbH of Switzerland to its growing list of international distribution partners, now spanning Australia, Canada, Croatia, Hungary,...

Intramuscular hepatitis B immunoglobulin offers advantages to liver recipients.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Intramuscular hepatitis B immunoglobulin offers advantages to liver recipients. According to a study from Italy, "the combination of lamivudine and hepatitis B immunoglobulins (HBIg) to prevent...

CRO selected to manage phase II trial of forodesine hydrochloride.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- BBCI, an international contract research organization, announced that it is providing clinical trial management services to BioCryst Pharmaceuticals, Inc., for its recently initiated phase IIa trial...

European survey identifies need for more education surrounding clinical trials.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Forty-two percent of Europeans surveyed would be more likely to participate in a clinical research study if they were aware of the measures in place to protect them. These findings come from more...

Serum IgE levels elevated in pediatric idiopathic nephrotic syndrome.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Serum IgE levels are elevated in pediatric idiopathic nephrotic syndrome patients, regardless of disease state. In a study from India, "[s]erum immunoglobulin E (IgE) and absolute eosinophil count...

FDA grants approval for ciprofloxacin in eye conditions.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Bausch & Lomb (BOL) has received U.S. Food and Drug Administration approval of the company's Abbreviated New Drug Application (ANDA) to manufacture and sell ciprofloxacin ophthalmic solution USP, 0.3%....

Diabetic men are at greater risk for developing erectile dysfunction.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Men being treated for diabetes are three times more likely to have erectile dysfunction (ED) than men in the general population. In addition, more than 50% of diabetic men develop ED within 10...

Findings may lead to testosterone patch for women with sexual dysfunction.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- A study on testosterone therapy may pave the way for a testosterone patch for women to treat sexual dysfunction. John Buster of Baylor College of Medicine and researchers from around the world...

P19(ARF) sustains normal cell proliferation rate during pregnancy.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- P19(ARF) functions primarily to sustain normal cell proliferation in mammary gland development during pregnancy, researchers report. "This study demonstrated, for the first time, the following...

Researchers compare two methods of diagnosing congestive heart failure.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- For patients with congestive heart failure (CHF) and reduced ejection fraction, early diastolic transmitral velocity/tissue Doppler mitral annular velocity (E/Ea) had higher specificity than "B-type...

iTopia Epitope Discovery System launched for immune response prediction.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Beckman Coulter, Inc., (BEC) announced the commercial availability of its new iTopia Epitope Discovery System, which incorporates a proprietary technology announced last year at the World Vaccine...

Drug delivery firm elects new directors.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Bentley Pharmaceuticals, Inc., (BNT) announced that stockholders elected two new members to 3-year terms on Bentley's board of directors. Those elected to the Board are F. Ross Johnson, the Chairman...

Leptin signaling targets thyrotropin-releasing hormone gene promoter.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Leptin signaling targets the thyrotropin-releasing hormone gene promoter. According to a study from the United States, "The regulation of TRH gene expression in the paraventricular nucleus of the...

Study: MammoPad reduces discomfort of mammography.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- A recently published study by Professor Laszlo Tabar, MD, confirms the MammoPad breast cushion significantly reduces the discomfort many women feel during mammograms. Gail S. Lebovic, MD,...

Pharmaceutical company files for initial public offering.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- BioNumerik Pharmaceuticals, Inc., announced that it has filed a registration statement for the initial public offering of shares of its common stock. The underwriters of the offering will be UBS...

Preliminary solid tumor data for clofarabine reported at ASCO.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Bioenvision, Inc., (BIV) announced that preliminary data from a phase I trial of clofarabine for the treatment of solid tumors was presented at the 40th Annual Meeting of American Society of Clinical...

Agreement signed for integrated software to life science researchers.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Biomax Solutions, Inc., of Falmouth, Massachusetts, and Geospiza, Inc., of Seattle, Washington, have announced the formation of an alliance and reseller relationship to integrate bioinformatics systems...

Merck, KGaA, returns Theratope rights.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Biomira, Inc., (BIOM) and Merck, KGaA, of Darmstadt, Germany, announced that development and commercialization rights to the therapeutic cancer vaccine, Theratope, will be returned to Biomira. The...

Significant survival advantage reported in phase III trial of Theratope.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Biomira, Inc., (BIOM, BRA) of Edmonton, Alberta, Canada, announced that an exploratory analysis showed a statistically significant survival advantage for women in the hormonal therapy subset of patients...

Study: Red wine dietary supplement may activate Sirtuin 1 gene.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- An independent laboratory test confirms that Longevinex, a red wine dietary supplement, exhibits significant biological activity, potently activating the Sirtuin 1 gene, known as a survival factor in...

Worldwide rights acquired for MRI-safe ceramic motor.
July 7, 2004... 2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Biophan Technologies, Inc., (BIPH) has signed an exclusive, worldwide distribution agreement with Victor, New York-based New Scale Technologies, Inc., for distribution of New Scale's ceramic "SQUIGGLE...